AstraZeneca: FDA approves Imfinzi in lung cancer
(CercleFinance.com) - AstraZeneca announces that the US FDA has approved Imfinzi (durvalumab) in the US to treat adults with stable limited small-cell lung cancer (LS-SCLC) after platinum-based chemotherapy and radiotherapy.
Based on the results of the Phase III ADRIATIC trial, this approval marks a major advance for this aggressive form of cancer.
Imfinzi demonstrated an improvement in median overall survival (55.9 months vs. 33.4 months for placebo) and reduced the risk of death by 27%.
No new safety signals have been identified, the laboratory said.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Based on the results of the Phase III ADRIATIC trial, this approval marks a major advance for this aggressive form of cancer.
Imfinzi demonstrated an improvement in median overall survival (55.9 months vs. 33.4 months for placebo) and reduced the risk of death by 27%.
No new safety signals have been identified, the laboratory said.
Copyright (c) 2024 CercleFinance.com. All rights reserved.